Healthcare
Stimcell Energetics, Inc.(STME)
Live Price
Offline$0.3474
-0.44% today
1Y Change
+38.61%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -782.4%
- Dividend Yield
- 0.0%
Coverage: 130 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stimcell Energetics, Inc. (STME) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.35 and up 38.6% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -782.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -782.4%, free cash flow +2.9% with operating margin 0.0% and ROIC 100.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STME price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jan 15, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -782.4%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +19.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jan 15, 2026 | โ | -1.4% | -17.6% | -38.0% |
2025 Oct 13, 2025 | โ | +36.4% | +30.9% | +3.0% |
2025 Aug 27, 2025 | โ | +0.0% | +44.4% | +77.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STME
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STME Max Drawdown
-47.90%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STME and SPY.
Company Overview
Stimcell Energetics, Inc.
Other OTC
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
- Leadership
- David Jeffs
- IPO Date
- Aug 29, 2013
- Employees
- 1
- Street Address
- 1130 Pender Street, West
- Mailing
- Vancouver, BC, V6E 4A4
- Region
- Vancouver, BC, CA
- Reporting Currency
- USD
- Investor Line
- 844 238 2692
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -782.4%
- Free Cash Flow
- +2.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 60.4%
- ROIC
- 100.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.